NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that Brian H. Annex, MD has accepted an appointment to the Company’s Scientific Advisory Board.
